[The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma]

Zhonghua Bing Li Xue Za Zhi. 2019 Apr 8;48(4):288-292. doi: 10.3760/cma.j.issn.0529-5807.2019.04.005.
[Article in Chinese]

Abstract

Objective: To investigate the prevalence of BRAF V600E mutation in thyroid nodules and to analyze the relationship between BRAF V600E mutation and various clinicopathological features. Methods: BRAF V600E mutant gene test was done in 463 cases of thyroid nodules collected from April 2015 to July 2018 in Beijing Hospital. Pathologic sections of 444 cases of papillary thyroid carcinoma were reviewed and clinical information was collected.Statistical analysis of the relationship between BRAF V600E gene mutation and various clinicopathological features was performed with SPSS 21.0 statistical software. Results: There were 109 males and 354 females in the cohort, with a male to female ratio of 1.0∶3.2. The patient ranged in age from 16 to 82 years, with an average age of 46.1 years. The BRAF V600E mutation rates in papillary thyroid carcinoma, benign thyroid nodules and other thyroid carcinoma were 86.5%(384/444),0/15 and 1/4,respectively.There was significant correlation between BRAF V600E mutation and histological diagnosis of papillary thyroid carcinoma (P<0.05). There was no correlation with age, gender, multifocality, bilaterality, coexisting lymphocytic thyroiditis, nodular goiter, maximum diameter, capsule invasion, extrathyroidal extension and clinical stage (P>0.05). Conclusions: BRAF V600E gene mutation is closely related to the occurrence of papillary thyroid carcinoma. BRAF V600E has significant value in the diagnosis of papillary thyroid carcinoma. While BRAF V600E mutation is related to the histological diagnosis, it shows no correlation with other clinicopathologic features. BRAF V600E mutation is not an independent prognostic factor in papillary thyroid carcinoma patients.

目的: 通过检测甲状腺BRAF V600E基因突变情况,分析其基因突变与甲状腺乳头状癌(PTC)及其临床病理特征之间的关系。 方法: 收集2015年4月至2018年7月北京医院病理科甲状腺BRAF V600E基因检测标本463例,并复阅术后病理诊断为PTC的标本444例,收集其临床病理信息。应用SPSS 21.0统计软件,分析BRAF V600E基因突变与PTC及其临床病理特征之间的关系。 结果: 甲状腺BRAF V600E基因检测标本463例,男性109例,女性354例,男女比为1.0∶3.2。患者年龄范围16~82岁,平均年龄46.1岁。PTC、甲状腺良性病变及甲状腺其他类型癌的BRAF V600E突变率分别为86.5%(384/444)、0/15及1/4,差异有统计学意义(P<0.01)。BRAF V600E突变与PTC的组织学亚型(经典型和高细胞型)有关(P<0.05),而与年龄、性别、多灶、双发、伴淋巴细胞性甲状腺炎、伴结节性甲状腺肿、肿瘤最大径、被膜侵犯、腺外侵犯、临床分期均无明显相关性(P>0.05)。 结论: BRAF V600E基因突变与PTC的发生密切相关,BRAF V600E突变与PTC的组织学亚型有关,而与其他临床病理特征未见相关性,尚不能作为甲状腺乳头状癌的独立预后因子。.

Keywords: Carcinoma, papillary; Prognosis; Thyroid neoplasms.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Papillary / diagnosis
  • Carcinoma, Papillary / genetics*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Prognosis
  • Proto-Oncogene Proteins B-raf / genetics*
  • Thyroid Cancer, Papillary / diagnosis
  • Thyroid Cancer, Papillary / genetics*
  • Thyroid Neoplasms / diagnosis
  • Thyroid Neoplasms / genetics*
  • Thyroid Nodule / diagnosis
  • Thyroid Nodule / genetics*
  • Young Adult

Substances

  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf